Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.

Abstract

Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months, causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation abnormalities, which may occur in almost all of the severe and critical ill COVID-19 cases. Concomitant venous thromboembolism (VTE), a potential cause of unexplained deaths, has been frequently reported in COVID-19 cases, but its management is still challenging due to the complexity between antithrombotic therapy and coagulation disorders. Based on frontline practical experience and comprehensive literature review, here a panel of experts and physicians from China and Europe developed an evidence and opinion-based consensus on the prophylaxis and management of VTE associated with COVID-19. This statement aims for clinicians treating COVID-19 and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed. With limited experience on COVID19-associated VTE, this expert consensus statement should be helpful for clinicians worldwide with specific suggestions.

• Authors: Zhenguo Zhai, Chenghong Li, Yaolong Chen, Grigorios Gerotziafas, Zhenlu Zhang, Jun Wan, Peng Liu, Ismaïl Elalamy, Chen Wang, Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group
• Journal: Thrombosis and haemostasis (Thromb Haemost) Vol. 120 Issue 6 Pg. 937-948 (Jun 2020) ISSN: 2567-689X [Electronic] Germany
• PMID: 32316065 (Publication Type: Journal Article, Review)
• Copyright: Georg Thieme Verlag KG Stuttgart · New York.

Chemical References

• Anticoagulants
• Fibrin Fibrinogen Degradation Products
• fibrin fragment D

Topics

• Anticoagulants (therapeutic use)
• Betacoronavirus
• Blood Coagulation Disorders (drug therapy)
• COVID-19
• China (epidemiology)
• Consensus
• Coronavirus Infections (blood, complications, therapy)
• Critical Illness
• Europe (epidemiology)
• Fibrin Fibrinogen Degradation Products (analysis)
• Hemorrhage (prevention & control)
• Humans
• Pandemics
• Pneumonia, Viral (blood, complications, therapy)
• Pulmonary Embolism (complications, prevention & control)
• Registries
• Risk Assessment
• Risk Factors
• SARS-CoV-2
• Treatment Outcome
• Venous Thromboembolism (complications, prevention & control, therapy)
• Venous Thrombosis (complications, prevention & control)